Sandoz, Boehringer Deal May Unlock Generic Competition for Ofev

Sandoz Inc. and Boehringer Ingelheim International GmbH agreed to a federal court judgment that Sandoz’s proposed copies of Ofev don’t infringe two patents for the rare-lung-disease treatment, potentially accelerating competition by allowing Sandoz to leapfrog other generics.

The consent decree and final judgment, which Judge Maryellen Noreika filed March 21, could clear the way for the Sandoz Group AG unit to launch its generic 100- and 150-milligram capsules of nintedanib, Ofev’s active ingredient, ahead of generic competitors who’d applied for US Food and Drug Administration approval before Sandoz. If Intas Pharmaceuticals Ltd.'s Accord Healthcare unit and Glenmark Pharmaceuticals Ltd. ...